Sun commences tender offer for Taro after merger collapsed

6 July 2008

India's Sun Pharmaceuticals has commenced its tender offer to acquire all outstanding ordinary shares of Israel's Taro following the bitter collapse of the firms' merger agreement (Marketletter June 9).

Sun's subsidiary Alkoloida is tendering the offer for the same cost as the merger (Marketletter May 28, 2007), $7.75 per share, under an option laid out in the terms of that deal. Taro's withdrawal from the agreement is being challenged by Sun in the New York State Supreme Court of the USA.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight